Nordic Nanovector - Fundamentale forhold 2019 (NANO)

sparkonge · november 20, 2019, 10:52am

"And that will give the reassurance that the efficacy data is above the needed hurdle for approval.”

F-Tosca · november 21, 2019, 2:24pm

Da er Jefferies-presentasjonen ute, ligger på hjemmesiden nå. Her er link.

TekBot · november 21, 2019, 6:06pm

Nordic Nanovector ASA - Financial calendar

Oslo, Norway, 21 November 2019

FINANCIAL YEAR 2019
…

Vis børsmeldingen

27.02.2020 - Quarterly Report - Q4

FINANCIAL YEAR 2020

17.04.2020 - Annual General Meeting

26.05.2020 - Quarterly Report - Q1

27.08.2020 - Half-yearly Report - Q2

19.11.2020 - Quarterly Report - Q3

The dates are subject to change. The time and location of the presentations will
be announced in due time.

This information is published pursuant to the requirements set out in the
Continuing obligations.

For further information, please contact:

IR enquiries

Malene Brondberg, VP Investor Relations and Corporate Communications

Cell: +44 7561 431 762

Email: ir@nordicnanovector.com

Media Enquiries

Mark Swallow/David Dible (Citigate Dewe Rogerson)

Tel: +44 207 638 9571

Email: nordicnanovector@citigatedewerogerson.com

About Nordic Nanovector:

Nordic Nanovector is committed to develop and deliver innovative therapies to
patients to address major unmet medical needs and advance cancer care. The
Company aspires to become a leader in the development of targeted therapies for
haematological cancers.

Nordic Nanovector’s lead clinical-stage candidate is Betalutin[®], a novel CD37
-targeting radioimmunotherapy designed to advance the treatment of non-Hodgkin’s
lymphoma (NHL). NHL is an indication with substantial unmet medical need,
representing a growing market forecast to be worth nearly USD 29 billion by
2026. Nordic Nanovector intends to retain marketing rights and to actively
participate in the commercialisation of Betalutin[®] in core markets.

Further information can be found at www.nordicnanovector.com.

This information is subject to a duty of disclosure pursuant to the Securities
Trading Act, Sections 4-2 and 5-12 / Oslo Stock Exchange’s Continuing
Obligations, Section 3.2.

Kilde

naboen · november 21, 2019, 6:18pm

Skvetter alltid litt til når det kommer mail fra Nano og norsk tipping.

Håper en av de slår inn🍾

Nocturne · november 21, 2019, 6:21pm

Dårlig timing. På vei til trening og måtte svinge av motorveien for å lese

pdx · desember 1, 2019, 10:00am

Hver måned kårer jeg det jeg kaller Teksperter™ for noen av de mest populære investeringene våre

Det er de 3 medlemmene som har fått flest likes på innleggene sine de siste 90 dagene. Teksperter™ får også en unikt merke på profilen sin og et trofé-ikon ved siden av navnet sitt. Du kan bli Tekspert™ i flere aksjer/investeringer, og troféet vil bare vises i tråder der du er Tekspert™.

Her er denne månedens Teksperter™ og det mest likte innlegget deres fra de siste 90 dagene:

@Savepig (686 likes)

@TyrionIV (541 likes)

@TheObserver (530 likes)

Resten av topp 10:

@Nocturne (496 likes)
@InVivo (481 likes)
@Fornybar (367 likes)
@FakeNews (220 likes)
@Inkognito666 (219 likes)
@Teejay (203 likes)
@vegar_beider (202 likes)

Gratulerer!

Savepig · desember 2, 2019, 11:22am

I dag har Nordic Nanovector fått ny CTO, som kommer direkte fra Bayer:

H.L · desember 2, 2019, 12:34pm

Imponerende CV fra Bayer… Kjøper dem opp hele sjappa nå?

F-Tosca · desember 2, 2019, 11:59pm

Presentasjonen fra QUL Life sciencekonferansen er ute, Marlene har vært på tur. København.

SpareGrizen · desember 3, 2019, 2:19pm

Ser at Company Presentation er oppdatert nå i desember: https://www.nordicnanovector.com/sites/default/files/link-documents/Corporate%20presentationDec.pdf

Kan ikke se at noen har kommentert dette før. Noen som klarer å huske hva som er oppdatert? Mulig jeg tar feil, men mener å tro at det er mer DLBCL fokus her enn tidligere?
Isåfall kan det muligens være eit lite frampeik?

Savepig · desember 3, 2019, 2:22pm

Nieba er kommet inn er det første åpenbare.

InVivo · desember 3, 2019, 2:23pm

Samme som lå ute tidligere i høst

SpareGrizen · desember 3, 2019, 2:31pm

Ok, takk for tilbakemelding.
Da var det sikkert bare mine «biased eyes» som leter etter godt DLBCL-nytt. Beklager.

Savepig · desember 3, 2019, 2:33pm

The Dual Cell Cycle Kinase Inhibitor JNJ-7706621 Reverses Resistance to CD37-Targeted Radioimmunotherapy in Activated B Cell Like Diffuse Large B Cell Lymphoma Cell Lines

SpareGrizen · desember 3, 2019, 2:40pm

Takk for at du deler. Meget interessant! Dette vil jo kunne styrke potensialet til Betalutin i DLBCL betraktelig.

Edit: Dog er det jo som vi vet langt mellom å påvise potensiale i utvalgte cellelinjer og in vivo.

InVivo · desember 3, 2019, 2:39pm

In conclusion, CD37-targeting 177Lu-lilotomab satetraxetan RIT showed activity in several ABC-DLBCL lymphoma cell lines. CD37-independent RIT-resistance was identified in two cell lines representative of aggressive DE ABC-DLBCLs with inactive TP53, and reversed by subsequent inhibition of CDK1/2 and AURKA/B by JNJ-7706621. These findings are of specific relevance for ongoing clinical trials of 177Lu-lilotomab satetraxetan in relapsed, ASCT-non-eligible DLBCL, and may also be more generally applicable to other 177Lu-based RITs and alternative radionuclide utilizing targeted therapies. Future pre-clinical investigations are required to elucidate the potential application of CDK1/2 and AURKA/B inhibitors as a strategy to revert RIT resistance in TP53 deficient cancers.

Savepig · desember 3, 2019, 2:55pm

https://ashpublications.org/blood/article/134/12/946/374911/High-frequency-of-inactivating-tetraspanin-CD37

InVivo · desember 3, 2019, 3:24pm

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5201094/

TekBot · desember 4, 2019, 6:01am

Nordic Nanovector: New preclinical data offer insights into enhancing Betalutin®-based therapies in NHL

Oslo, Norway, 4 December 2019

Nordic Nanovector ASA (OSE: NANO) announces that new data from preclinical
…

Vis børsmeldingen

studies investigating the effect of Betalutin® ([177]Lu-lilotomab satetraxetan)
on non-Hodgkin’s lymphoma (NHL) cell lines will be presented in a poster at the
61[st] American Society of Hematology (ASH) Annual Meeting & Exposition (7-10
December 2019 in Orlando, FL, USA).

The ongoing research programme aims to investigate resistance mechanisms that
enable NHL cells to survive Betalutin® treatment and to identify molecules that,
when used in combination with Betalutin®, could overcome that resistance. The
findings of this research could direct future programmes designed to expand the
use of Betalutin®-based therapies in NHL patients.

The research being presented at ASH builds on data previously presented (at the
European Haematology Association annual meeting in June 2018) describing how a
screen of more than 50 different NHL cell lines identified some cell lines that
were resistant to Betalutin®. Two resistant cell lines were aggressive diffuse
large B-cell lymphoma (DLBCL) cell lines (the double-hit/double-expressor ABC
-DLBCL cell lines RIVA and U2932).

The new poster reports how these two aggressive DLBCL cell lines have been used
in a new screen where Betalutin® has been combined with 384 different anti
-cancer drugs to identify the Betalutin®/drug combinations that could
potentially contribute to reverting resistance.

Jostein Dahle, Chief Scientific Officer of Nordic Nanovector, said: “Our ongoing
research programmes and collaborations continue to help us understand how NHL
cells react to Betalutin® treatment. Understanding the mechanisms of resistance
to Betalutin®, and how to overcome them, is crucial for being able to deliver
optimal treatment to patients with difficult to treat tumours. In the case of
Betalutin®-based treatment, which to date has demonstrated an encouraging
clinical profile, such combination strategies could further enhance its
potential to become an important option for NHL patients.”

Abstract 2574

Abstract title: The Dual Cell Cycle Kinase Inhibitor JNJ-7706621
Reverses Resistance to CD37 Targeted Radioimmunotherapy in Activated B Cell like
Diffuse Large B Cell Lymphoma Cell Lines

Authors: G.E. Rødland et al.

Session Name: 605. Molecular Pharmacology, Drug Resistance-Lymphoid and
Other Diseases: Poster II

Date: Sunday, 8 December 2019

Presentation Time: 6:00 PM - 8:00 PM Eastern time

Location: Orange County Convention Center, Hall B

The abstract is available at
https://ash.confex.com/ash/2019/webprogram/Paper123287.html and the poster will
be published on the Nordic Nanovector website to coincide with the session.

About ASH

The ASH annual meeting is the premier event for scientific exchange in the field
of haematology, attracting more than 20,000 attendees from all over the world.
Typically, more than 5,000 scientific abstracts are submitted each year, and
more than 3,000 abstracts are accepted for oral and poster presentations through
an extensive peer review process. https://hematology.org/Annual-Meeting/

For further information, please contact:

IR enquiries

Malene Brondberg, VP Investor Relations and Corporate Communications

Cell: +44 7561 431 762

Email: ir@nordicnanovector.com

Media Enquiries

Mark Swallow/David Dible (Citigate Dewe Rogerson)

Tel: +44 207 638 9571

Email: nordicnanovector@citigatedewerogerson.com

About Nordic Nanovector:

Nordic Nanovector is committed to develop and deliver innovative therapies to
patients to address major unmet medical needs and advance cancer care. The
Company aspires to become a leader in the development of targeted therapies for
haematological cancers.

Nordic Nanovector’s lead clinical-stage candidate is Betalutin®, a novel CD37
-targeting radioimmunotherapy designed to advance the treatment of non-Hodgkin’s
lymphoma (NHL). NHL is an indication with substantial unmet medical need,
representing a growing market forecast to be worth nearly USD 29 billion by
2026. Nordic Nanovector intends to retain marketing rights and to actively
participate in the commercialisation of Betalutin® in core markets.

Further information can be found at www.nordicnanovector.com.

Forward-looking statements

This press release contains certain forward-looking statements. These
statements are based on management’s current expectations and are subject to
uncertainty and changes in circumstances, since they relate to events and depend
on circumstances that will occur in the future and which, by their nature, will
have an impact on Nordic Nanovector’s business, financial condition and results
of operations. The terms “anticipates”, “assumes”, “believes”, “can”, “could”,
“estimates”, “expects”, “forecasts”, “intends”, “may”, “might”, “plans”,
“should”, “projects”, “targets”, “will”, “would” or, in each case, their
negative, or other variations or comparable terminology are used to identify
forward-looking statements. These forward-looking statements are not historic
facts. There are a number of factors that could cause actual results and
developments to differ materially from those expressed or implied in the forward
-looking statements. Factors that could cause these differences include, but are
not limited to, risks associated with implementation of Nordic Nanovector’s
strategy, risks and uncertainties associated with the development and/or
approval of Nordic Nanovector’s product candidates, ongoing and future clinical
trials and expected trial results, the ability to commercialise Betalutin®,
technology changes and new products in Nordic Nanovector’s potential market and
industry, Nordic Nanovector’s freedom to operate (competitors patents) in
respect of the products it develops, the ability to develop new products and
enhance existing products, the impact of competition, changes in general economy
and industry conditions, and legislative, regulatory and political factors. No
assurance can be given that such expectations will prove to have been correct.
Nordic Nanovector disclaims any obligation to update or revise any forward
-looking statements, whether as a result of new information, future events or
otherwise.

This information is subject to a duty of disclosure pursuant to Sections 4-2 and
5-12 of the Securities Trading Act.

Kilde

H.L · desember 4, 2019, 6:42am

Er vel ikke tilfeldig at de har rekruttert en CTO fra Bayer? Må være noe han ser i NANO som kommer til å bli attraktiv for BP i fremtiden